SGMT · Insider Trading
Sagimet Biosciences Inc. Series A Common Stock
Every open-market purchase and sale reported by SGMT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | George Kemble | Director | MIXED | — | −$1.36M |
| 2026-08-12 | George Kemble | Director | MIXED | — | −$72.64K |
| 2026-07-22 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | −10,545 | −$81.83K |
| 2026-07-22 | David Happel | President & CEO | Sell | −64,051 | −$497.07K |
| 2026-07-22 | George Kemble | Director | Sell | −18,844 | −$140.53K |
| 2026-06-15 | Beth C Seidenberg | Director | A | +39,567 deriv. | — |
| 2026-06-15 | Paul W. Hoelscher | Director | A | +39,567 deriv. | — |
| 2026-06-15 | Anne M. Phillips | Director | A | +39,567 deriv. | — |
| 2026-06-15 | George Kemble | Director | A | +39,567 deriv. | — |
| 2026-06-15 | Jennifer Jarrett | Director | A | +39,567 deriv. | — |
| 2026-06-15 | Elizabeth A Grammer | Director | A | +39,567 deriv. | — |
| 2026-06-01 | Andreas Grauer | Chief Medical Officer | A | +35,000 deriv. | — |
| 2026-06-01 | David Happel | President & CEO | A | +300,000 deriv. | — |
| 2026-06-01 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | +100,000 deriv. | — |
| 2026-06-01 | Thierry Chauche | Chief Financial Officer | A | +50,000 deriv. | — |
| 2026-05-14 | Andreas Grauer | Chief Medical Officer | A | +264,759 deriv. | — |
| 2026-02-20 | Thierry Chauche | Chief Financial Officer | A | +44,000 | — |
| 2026-02-20 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | +44,000 | — |
| 2026-02-20 | David Happel | President & CEO | A | +128,000 | — |
| 2026-02-20 | Eduardo Bruno Martins | Chief Medical Officer | A | +44,000 | — |
| 2026-02-12 | Thierry Chauche | Chief Financial Officer | Sell | −1,312 | −$7.03K |
| 2026-02-12 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | −2,622 | −$14.05K |
| 2026-02-12 | Eduardo Bruno Martins | Chief Medical Officer | Sell | −3,640 | −$19.51K |
| 2026-02-12 | David Happel | President & CEO | Sell | −12,101 | −$64.86K |
| 2025-11-21 | George Kemble | Executive Chairman | Sell | −37,688 | −$289.98K |
| 2025-11-06 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | +9,855 | — |
| 2025-07-23 | Eduardo Bruno Martins | Chief Medical Officer | Sell | −8,277 | −$75.61K |
| 2025-07-23 | David Happel | President & CEO | Sell | −65,478 | −$598.12K |
| 2025-07-23 | Elizabeth Rozek | General Counsel and CCO | Sell | −10,780 | −$98.47K |
| 2025-06-10 | Paul W. Hoelscher | Director | A | +32,250 deriv. | — |
| 2025-06-10 | Elizabeth A Grammer | Director | A | +32,250 deriv. | — |
| 2025-06-10 | Anne M. Phillips | Director | A | +27,268 deriv. | — |
| 2025-06-10 | Timothy P Walbert | Director | A | +32,250 deriv. | — |
| 2025-06-10 | George Kemble | Director | A | +32,250 deriv. | — |
| 2025-06-10 | Beth C Seidenberg | Director | A | +60,772 deriv. | — |
| 2025-06-10 | Jennifer Jarrett | Director | A | +27,268 deriv. | — |
| 2025-02-07 | Elizabeth Rozek | General Counsel and CCO | A | +34,000 | — |
| 2025-02-07 | David Happel | President & CEO | A | +116,000 | — |
| 2025-02-07 | Thierry Chauche | Chief Financial Officer | A | +17,000 | — |
| 2025-02-07 | Eduardo Bruno Martins | Chief Medical Officer | A | +34,000 | — |
| 2024-08-05 | Jennifer Jarrett | Director | A | +113,895 deriv. | — |
| 2024-08-05 | Anne M. Phillips | Director | A | +113,895 deriv. | — |
| 2024-07-25 | George Kemble | Executive Chairman | Sell | −23,625 | −$74.83K |
| 2024-07-23 | Elizabeth Rozek | General Counsel and CCO | Sell | −10,914 | −$33.83K |
| 2024-07-23 | George Kemble | Executive Chairman | Sell | −14,062 | −$43.60K |
| 2024-07-23 | Eduardo Bruno Martins | Chief Medical Officer | Sell | −8,357 | −$25.91K |
| 2024-06-07 | Beth C Seidenberg | Director | A | +51,459 deriv. | — |
| 2024-06-07 | Elizabeth A Grammer | Director | A | +51,459 deriv. | — |
| 2024-06-07 | Timothy P Walbert | Director | A | +9,279 deriv. | — |
| 2024-06-07 | Merdad Parsey | Director | A | +51,459 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Happel | President & CEO | 741,570 | $7.09M |
| George Kemble | Executive Chairman | 413,148 | $3.95M |
| Elizabeth Rozek | Chief Legal & Admin. Officer | 224,414 | $2.15M |
| Eduardo Bruno Martins | Chief Medical Officer | 147,296 | $1.41M |
| Beth C Seidenberg | Director | 84,768 | $810.38K |
| Thierry Chauche | Chief Financial Officer | 59,688 | $570.62K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SGMT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.